Deciphera Prepares To Collect Revenue After First FDA Approval: 'We Are Well-Positioned'
After 17 years of clinical work, Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) finally has a marketable product. The Food and Drug Administration approved Qinlock as a fourth-line treatment of gastrointestinal stromal tumors earlier this month.
